XML 108 R69.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information - Schedule of Financial Data for Reportable Segment (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]    
Research and development expenses $ 63,992 $ 46,024
General and administrative expenses 25,207 21,079
Net loss (80,556) (60,388)
Reportable Segment    
Segment Reporting Information [Line Items]    
General and administrative expenses 25,207 21,079
Other segment items [1] (8,643) (6,715)
Net loss (80,556) (60,388)
ACR-368 | Reportable Segment    
Segment Reporting Information [Line Items]    
Research and development expenses 34,135 21,764
ACR-2316 | Reportable Segment    
Segment Reporting Information [Line Items]    
Research and development expenses [2] 3,384  
Other Drug Discovery Programs | Reportable Segment    
Segment Reporting Information [Line Items]    
Research and development expenses 4,037 6,982
Personnel | Reportable Segment    
Segment Reporting Information [Line Items]    
Indirect research and development expenses 18,184 13,987
Facilities Supplies And Other | Reportable Segment    
Segment Reporting Information [Line Items]    
Indirect research and development expenses $ 4,252 $ 3,291
[1] Other segment items consist of interest income and other expense, net. Interest income consists of interest income earned on cash equivalents and investments and amortization of premiums and accretion of discounts to maturity for available-for-sale debt securities. Other expense, net primarily consists of realized and unrealized gains and losses on foreign currency transactions, state taxes, and investment management fees
[2] ACR-2316 direct research and development expenses include costs related to the Company’s novel, internally-discovered second clinical stage asset, which was promoted to a development program upon being granted IND clearance in the third quarter of 2024 and includes clinical trial and related activities. Prior to IND clearance, costs related to preclinical drug discovery activities progression related to ACR-2316 were included in other drug discovery programs direct research and development expenses.